» Articles » PMID: 39045234

Exploring the Underlying Molecular Mechanisms of Acute Myocardial Infarction After SARS-CoV-2 Infection

Overview
Journal Am Heart J Plus
Date 2024 Jul 24
PMID 39045234
Authors
Affiliations
Soon will be listed here.
Abstract

An increase in acute myocardial infarction (AMI)-related deaths has been reported during the COVID-19 pandemic. Despite evidence suggesting the association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and AMI, the underlying mechanisms remain unclear. Here, we integrated mRNA and microRNA expression profiles related to SARS-CoV-2 infection and AMI from public databases. We then performed transcriptomic analysis using bioinformatics and systems biology approaches to explore the potential molecular mechanisms of SARS-CoV-2 infection affects AMI. First, twenty-one common differentially expressed genes (DEGs) were identified from SARS-CoV-2 infection and AMI patients in endothelial cells datasets and then we performed functional analysis to predict the roles of these DEGs. The functional analysis emphasized that the endothelial cell response to cytokine stimulus due to excessive inflammation was essential in these two diseases. Importantly, the tumor necrosis factor and interleukin-17 signaling pathways appeared to be integral factors in this mechanism. Interestingly, most of these common genes were also upregulated in transcriptomic datasets of SARS-CoV-2-infected cardiomyocytes, suggesting that these genes may be shared in cardiac- and vascular-related injuries. We subsequently built a protein-protein interaction network and extracted hub genes and essential modules from this network. At the transcriptional and post-transcriptional levels, regulatory networks with common DEGs were also constructed, and some key regulator signatures were further identified and validated. In summary, our research revealed that a highly activated inflammatory response in patients with COVID-19 might be a crucial factor for susceptibility to AMI and we identified some candidate genes and regulators that could be used as biomarkers or potential therapeutic targets.

Citing Articles

Oncogenic potential of SARS-CoV-2-targeting hallmarks of cancer pathways.

Jaiswal A, Shrivastav S, Kushwaha H, Chaturvedi R, Singh R Cell Commun Signal. 2024; 22(1):447.

PMID: 39327555 PMC: 11426004. DOI: 10.1186/s12964-024-01818-0.

References
1.
Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J, Turner A . Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020; 126(10):1456-1474. PMC: 7188049. DOI: 10.1161/CIRCRESAHA.120.317015. View

2.
Hendren N, Drazner M, Bozkurt B, Cooper Jr L . Description and Proposed Management of the Acute COVID-19 Cardiovascular Syndrome. Circulation. 2020; 141(23):1903-1914. PMC: 7314493. DOI: 10.1161/CIRCULATIONAHA.120.047349. View

3.
Varga Z, Flammer A, Steiger P, Haberecker M, Andermatt R, Zinkernagel A . Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395(10234):1417-1418. PMC: 7172722. DOI: 10.1016/S0140-6736(20)30937-5. View

4.
Love M, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014; 15(12):550. PMC: 4302049. DOI: 10.1186/s13059-014-0550-8. View

5.
Sardu C, Gambardella J, Morelli M, Wang X, Marfella R, Santulli G . Hypertension, Thrombosis, Kidney Failure, and Diabetes: Is COVID-19 an Endothelial Disease? A Comprehensive Evaluation of Clinical and Basic Evidence. J Clin Med. 2020; 9(5). PMC: 7290769. DOI: 10.3390/jcm9051417. View